August 31, 2016 Columns by admin Welcome or Not, FDA Focuses on Stem Cell Treatments News that the U.S. Food and Drug Administration (FDA) is to hold a public hearing next month to consider greater oversight of stem cell clinics operating in the country is as welcome as it is late. I say “late” because, while the regulators have been twiddling their fingers,…
August 30, 2016 News by Patricia Silva, PhD TG Therapeutics’ Potential Neuromyelitis Optica Treatment Named Orphan Drug by FDA TheĀ U.S. Food and Drug AdministrationĀ (FDA) has designated TG-1101Ā (ublituximab), aĀ glycoengineered anti-CD20 monoclonal antibody byĀ TG Therapeutics, anĀ orphan drugĀ to advance its development. The drug is a potentialĀ treatment for neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD), two relapsing-remitting autoimmune diseases with similarities to multiple sclerosis. Currently, there are…
August 9, 2016 News by Patricia Silva, PhD PCORI Awards $2 Million to Study Treatments for Fatigue in MS Patients The Patient-Centered Outcomes Research Institute (PCORI) recentlyĀ awarded a sum of $5.5 million to two researchers at the University of California, San FranciscoĀ (UCSF). Bardia Nourbakhsh, MD. (Credit: UCSF) Bardia Nourbakhsh, MD, a clinical fellow in Neurology, receivedĀ aĀ $2 million grant to conduct a randomized, double-blind, placebo-controlled clinical trial to…
August 3, 2016 Columns by admin Stem Cell Clinics Under Critical Scrutiny in US Stem cell clinics are proliferating in the U.S., where there are now 570 in operation, according to a paper quoted by the New York Times. And concerns are being raised that these clinics are often operating and making claims beyond those allowed by the countryās public health regulatory…
July 15, 2016 Columns by admin Patients Need To Know What Drugs Do Inside Our Bodies Oral therapy Tecfidera (dimethyl fumarate) seems to be emerging as a first-line treatment for relapsing multiple sclerosis ā according to Biogen, the company that developed it. Thatās good news, and something we need to know. The company agrees that for some time, the long-term effectiveness and safety of this oral…
June 29, 2016 News by InĆŖs Martins, PhD 1st Potential Therapy for Primary Progressive MS, Ocrelizumab, Under Priority Review by FDA The U.S. Food and Drug Administration (FDA) is givingĀ priority review to a request to approveĀ Ocrevus (ocrelizumab) as a treatment forĀ both forms of multiple sclerosis, the drug’s developer,Ā Genentech, announced. If the company’s Biologics License Application (BLA) is approved,Ā Ocrevus will become the first drug ableĀ to treat patients with either relapsing or…
May 31, 2016 News by Patricia Silva, PhD Multiple Sclerosis treatment Zinbryta (Daclizumab) Approved by FDA Zinbryta (daclizumab) was approved May 27 for the treatment of adults with relapsing multiple sclerosis (MS). The U.S. Food and Drug Administration (FDA) cleared Biogenās new long-acting injection as a patient self-administered monthly therapy. The director of Neurology Products at the U.S. FDAās Center for Drug Evaluation…
April 11, 2016 News by Margarida Azevedo, MSc PathMaker Launches Clinical Trial of MyoRegulator to Treat Spasticity, Common in MS PathMaker Neurosystems, Inc.,Ā recently announced the launch of anĀ Institutional Review Board (IRB)-approvedĀ clinical trial, in partnership with Northwell Health (formerly North Shore-LIJ Health System) andĀ The Feinstein Institute for Medical Research,Ā to evaluate the safety and efficacy ofĀ MyoRegulator for the treatment of spasticity, one of the most common symptoms in multiple sclerosis…
March 23, 2016 News by Patricia Silva, PhD Potential Progressive MS Treatment, Ibudilast, Approved for Fast Track Development by FDA MediciNova, Inc.,Ā announced that MN-166 (ibudilast) has been approved for “fast track” development byĀ the U.S. Food and Drug Administration (FDA)Ā as a potentialĀ treatment forĀ progressive multiple sclerosis (MS).Ā Progressive MS includesĀ both the primary progressive (PPMS) and secondary progressive (SPMS) forms of the disease. MediciNovaās MN-166 was licensed from Kyorin Pharmaceuticals for its potential…
February 18, 2016 News by BioNews Staff FDA Grants ‘Breakthrough Therapy’ Designation to Genentechās Ocrelizumab for PPMS Genentech recently announced that the U.S. Food and Drug Administration (FDA) granted its investigational medicine ocrelizumab, a potential treatment forĀ primary progressive multiple sclerosis (PPMS),Ā Breakthrough Therapy DesignationĀ based on positiveĀ Phase 3 clinical trial results showing thatĀ ocrelizumab significantly reduced disability progression and other disease activity markers compared toĀ placebo. The FDA designation is…
January 21, 2016 News by Charles Moore FDA Invites Comment on Pending Stem Cell Therapy Regulations The U.S. Food and Drug Administration (FDA) will hold a one-day public hearingĀ on four recent draft guidelines regarding theĀ regulation of human cells, tissues, or cellular or tissue-based products (HCT/Ps). Critics of the proposed regulations warnĀ that they curtail the medical use of autologous cell therapy and biologics, and their future potential…
January 20, 2016 News by Patricia Silva, PhD Potential MS Stem Cell Therapy Moves into Phase 2 Trial for 1st Time in US The Tisch MS Research Center of New York (Tisch MSRCNY) recently announced that its stem cell-based therapy as a potential treatment for multiple sclerosis (MS) will move into Phase 2 clinical testingĀ after encouraging results in a Phase 1 trial, and on the advice of Ā the U.S. Food and Drug…
November 4, 2015 News by Patricia Silva, PhD Alkermes’ Multiple Sclerosis Therapy ALKS 8700 Yields Positive Clinical Trial Data Alkermes plc, a fully integrated global biopharmaceutical company, recently provided a regulatory update and positive clinical trial data for ALKS 8700, an oral, innovativeĀ and proprietary monomethyl fumarate (MMF) compound that is being developed to treat multiple sclerosis (MS). ALKS 8700 is being developed to quickly and efficiently convert…
November 2, 2015 News by Patricia Silva, PhD New Muscle Spasticity Therapy Under Priority Review by FDA PathMaker Neurosystems Inc., a clinical-stage neuromodulation company focused on non-invasive therapies for neuromotor disorders, recently announced that the U.S. Food and Drug Administration (FDA) has granted the companyās MyoRegulatorā¢ PM-2200 systemĀ the Expedited Access Pathway (EAP) designation and priority processing status. The MyoRegulator is the first product of PathMaker…
August 5, 2015 News by Patricia Silva, PhD Cases of Brain Infection Reported in MS Patients Taking Gilenya Multiple sclerosis patients prescribed Gilenya (fingolimod) are now being informed about a handful of documented cases where the therapy was found to have led to a rareĀ brain infection, according toĀ the US Food and Drug Administration. The FDA has released a public warning indicating thatĀ cases ofĀ progressive multifocal leukoencephalopathy (PML) have been…
July 16, 2015 News by admin Study Shows Skin Problems Can Be Caused by Interferon-Ī² MS Therapy Skin problems may be caused by interferon-Ī², a common treatment for multiple sclerosis (MS), according to a new study published by a German research group at the Klinik und Poliklinik fĆ¼r Dermatologie, Venerologie und Allergologie, in WĆ¼rzburg, Germany. The work, entitled “Cutaneous Adverse Events Associated with Interferon-Ī²…
July 14, 2015 News by admin Nano-Drugs in Liposomes Could Treat Multiple Sclerosis Nano-drugs encased in liposomes could one day be used to treat neurological diseases like multiple sclerosis (MS), according to a new study published July 6th in the journal, PloS One. A liposome is a small, fat soluble droplet that can contain a water soluble drug. Liposomes might…
June 16, 2015 News by BioNews Staff FDA Taps Online Patient Database To Gain Access To Patient-Reported MS Health Data In an effort to access firsthand patient data as a means of improving healthcare and drug safety, the Food and Drug Administration (FDA) hasĀ announced a unique partnership withĀ Ā PatientsLikeMe, an online network of 350,000 patients who have reported on their own personal experiences in living with over 2,500 different diseases. The…
May 14, 2015 News by admin PA Hospital Begins Offering LEMTRADA as Treatment for Relapsing Multiple Sclerosis The Allegheny General Hospital in Pennsylvania is now offering a new treatment option for people with relapsing remitting multiple sclerosisĀ (RRMS) — the most common form of multiple sclerosis.Ā Ā The treatment may help people with RRMS who have not responded to other medications. MS is an autoimmune disorder in which the…
May 7, 2015 News by admin Myelin Repair Foundation and NIH to Study Guanabenz for MS The Myelin Repair Foundation (MRF) and National Institutes of HealthĀ (NIH)Ā will initiateĀ a clinical trial of guanabenz in people with multiple sclerosis (MS). Guanabenz is FDA-approved for high blood pressure, but it may also prevent myelin loss. The drug could be the first for MS to protect myelin from…
May 6, 2015 News by Patricia Silva, PhD FDA Evaluates ZINBRYTA For MS Treatment The U.S. Food and Drug Administration (FDA) has announced it willĀ considerĀ marketing approval ofĀ ZINBRYTA (daclizumab high-yield process), a potential treatment for relapsing forms of multiple sclerosis (MS). Biogen and AbbVie, who are jointly developing the therapy, have filed aĀ Biologics License Application…
May 1, 2015 News by admin Genzyme’s LEMTRADA Maintain’s Effectiveness in Reducing Brain Atrophy According to Recent Study Results GenzymeĀ presentedĀ new magnetic resonance imaging (MRI) data from the LemtradaĀ® (alemtuzumab) clinical development programĀ onĀ April 23, 2015, at the 67th American Academy of Neurology (AAN) Annual Meeting. The company showed that in the extension phase of two Phase III trials (years 3 and 4), the drug continued to protect the nervous…
April 27, 2015 News by Patricia Silva, PhD FDA Accepts Bayerās BETACONNECT License Application for Relapsing-Remitting Multiple Sclerosis Bayer HealthCareĀ recently announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a supplemental Biologics License Application (sBLA) for BETACONNECT forĀ the treatment of relapsing-remitting multiple sclerosis (MS). BETACONNECT isĀ a new drug delivery option for patients under Bayerās BETASERONĀ® (interferon beta-1b) therapy. MS is a…
April 17, 2015 News by Patricia Silva, PhD First Generic Version of Copaxone Approved by FDA to Treat Multiple Sclerosis The U.S. Food and Drug Administration (FDA) has announced the approval of the first generic version ofĀ CopaxoneĀ (glatiramer acetate injection) for the treatment ofĀ relapsing forms of multiple sclerosis (MS). The administration has grantedĀ Sandoz marketing authorization forĀ glatiramer acetate in 20 mg/1 ml…
April 13, 2015 News by admin Biogen to Focus on RRMS Disease Management, Treatment at Upcoming Conference Biogen plans toĀ present new clinical data at the 67th American Academy of Neurology (AAN) Annual Meeting in Washington D.C., April 18 ā 25, 2015, including numerous presentations focusing on multiple sclerosis. Ā In a company press release, Biogen statedĀ āAt AAN, we will feature new scientific data, including research highlighting the…
December 8, 2014 News by Isaura Santos Ipsen Biopharmaceuticals Announces FDA To Review sBLA For DysportĀ® As Treatment For Upper Limb Spasticity Ipsen Biopharmaceuticals, IncĀ announced that the United States Food and Drug Administration (FDA) has agreed to review theĀ supplemental Biologics License Application (sBLA) for DysportĀ®Ā (abobotulinumtoxinA)Ā to treat upper limbĀ spasticity, a condition that affects many people in the United States, including multiple sclerosis (MS)…
December 1, 2014 News by Patricia Silva, PhD FDA Delays Ruling on Teva Petition Against Generic Copaxone for MS Teva Pharmaceutical Industries Ltd., the company behind multiple sclerosis drugĀ COPAXONEĀ® (glatiramer acetate injection), has been pursuing the US Food and Drug Administration‘s decision against approving a generic version of the drug, by Mylan, Inc.Ā Teva’s petition has been turned down several times,…
November 17, 2014 News by Patricia Silva, PhD Teva Pursues Regulatory Approval in Japan for MS Drug Copaxone Teva Pharmaceutical Industries Ltd., the company that developed the injectable multiple sclerosis treatment Copaxone (Glatiramer acetate), Ā has announced their pursuit of regulatory approval in Japan. This development comes a year after signing an agreement with Takeda Pharmaceutical Co. Ltd. According to a…
October 29, 2014 News by Patricia Inacio, PhD Experimental Multiple Sclerosis Drug Clears Key FDA Hurdle, To Be Tested in U.S. A new human clinical trial testing the drug ATL1102 to treat Multiple Sclerosis was approved by FDA, carrying the promise of new therapeutics to affected patients. Antisense Therapeutics Limited (ANP) announced recently in a press release the FDA’s positive decision to approve their request to submit an Investigational…
October 15, 2014 News by Patricia Silva, PhD Urinary Prosthesis Better than Catheterization for Female MS Patients One of the concerns patients with neurologic diseases such as multiple sclerosisĀ face is decline or loss of bladder control. It can be an embarrassing and frustrating problem, which is estimated to occur in about 80% of MS patients, as the disease causes a slowing down or interruption in signal transmission…